The Food and Drugs Authority (FDA) has approved the first herbal medicine for clinical trials for the treatment of COVID-19.
The herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima, was submitted by researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology (KNUST).
In a statement signed by Chief Executive Officer of FDA, Mrs. Delese A.A. Darko, it was disclosed that the clinical trial application for the efficacy of the medicine was submitted September, 2020 and was approved in January,2021.
“The Food and Drugs Authority (FDA), the National Medicine Regulatory Agency (NMRA) in Ghana, has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima for clinical trials in January 2021”. The statement read.
The FDA furthered this approval comes after “results from laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits”.
Below is the full statement: